Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 13130315)

  • 21. Autologous stem cell transplantation with selected CD34+ cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: a single centre experience.
    Ballova V; Ladicka M; Vranovsky A; Lakota J
    Neoplasma; 2008; 55(5):428-36. PubMed ID: 18665754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isolation of purified autologous peripheral blood CD34+ cells with low T cell content using CliniMACS device--a local experience.
    Leong CF; Habsah A; Teh HS; Goh KY; Fadilah SA; Cheong SK
    Malays J Pathol; 2008 Jun; 30(1):31-6. PubMed ID: 19108409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneous immunomagnetic CD34+ cell selection and B-cell depletion in peripheral blood progenitor cell samples of patients suffering from B-cell non-Hodgkin's lymphoma.
    Mohr M; Dalmis F; Hilgenfeld E; Oelmann E; Zühlsdorf M; Kratz-Albers K; Nolte A; Schmitmann C; Onaldi-Mohr D; Cassens U; Serve H; Sibrowski W; Kienast J; Berdel WE
    Clin Cancer Res; 2001 Jan; 7(1):51-7. PubMed ID: 11205918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab.
    Galimberti S; Guerrini F; Morabito F; Palumbo GA; Di Raimondo F; Papineschi F; Caracciolo F; Fazzi R; Cervetti G; Cuzzocrea A; Petrini M
    Bone Marrow Transplant; 2003 Jul; 32(1):57-63. PubMed ID: 12815479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
    Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
    Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
    Mandigers CM; Verdonck LF; Meijerink JP; Dekker AW; Schattenberg AV; Raemaekers JM
    Bone Marrow Transplant; 2003 Dec; 32(12):1159-63. PubMed ID: 14647270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.
    Perz JB; Giles C; Szydlo R; O'Shea D; Sanz J; Chaidos A; Wagner S; Davis J; Loaiza S; Marin D; Apperley J; Olavarria E; Rahemtulla A; Lampert I; Naresh K; Samson D; MacDonald D; Kanfer EJ
    Bone Marrow Transplant; 2007 Jan; 39(1):41-7. PubMed ID: 17115062
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma.
    Gribben JG; Freedman AS; Neuberg D; Roy DC; Blake KW; Woo SD; Grossbard ML; Rabinowe SN; Coral F; Freeman GJ
    N Engl J Med; 1991 Nov; 325(22):1525-33. PubMed ID: 1944436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autologous tandem transplantation in patients with primary progressive or relapsed/refractory lymphoma.
    Glossmann JP; Staak JO; Nogova L; Diehl V; Scheid C; Kisro J; Reis HE; Peter N; Engert A; Josting A
    Ann Hematol; 2005 Aug; 84(8):517-25. PubMed ID: 15759115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
    Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E;
    Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
    Wadhwa PD; Fu P; Koc ON; Cooper BW; Fox RM; Creger RJ; Bajor DL; Bedi T; Laughlin MJ; Payne J; Gerson SL; Lazarus HM
    Biol Blood Marrow Transplant; 2005 Jan; 11(1):13-22. PubMed ID: 15625540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monoclonal B cells detected in autologous PBSC grafts from patients with classical Hodgkin lymphoma: impact on relapse and survival following transplantation.
    Takach S; Yang L; Ho J; Sabri E; Martin L; Halpenny M; Atkins H; Sabloff M; McDiarmid SA; Huebsch LB; Bence-Bruckler I; Giulivi A; Allan DS
    Bone Marrow Transplant; 2010 May; 45(5):856-61. PubMed ID: 19767777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation.
    Serrano D; Carrión R; Balsalobre P; Miralles P; Berenguer J; Buño I; Gómez-Pineda A; Ribera JM; Conde E; Díez-Martín JL;
    Exp Hematol; 2005 Apr; 33(4):487-94. PubMed ID: 15781340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease.
    Ho VT; Kim HT; Li S; Hochberg EP; Cutler C; Lee SJ; Fisher DC; Milford E; Kao G; Daley H; Levin J; Ng A; Mauch P; Alyea EP; Antin JH; Soiffer RJ
    Bone Marrow Transplant; 2004 Dec; 34(11):987-94. PubMed ID: 15489873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device.
    van Heeckeren WJ; Vollweiler J; Fu P; Cooper BW; Meyerson H; Lazarus HM; Simic A; Laughlin MJ; Gerson SL; Koç ON
    Br J Haematol; 2006 Jan; 132(1):42-55. PubMed ID: 16371019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.
    Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Jang S; Park CJ; Chi HS; Huh J; Suh C
    Ann Hematol; 2007 Jun; 86(6):435-42. PubMed ID: 17256144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autologous stem-cell transplantation in patients with HIV-related lymphoma.
    Balsalobre P; Díez-Martín JL; Re A; Michieli M; Ribera JM; Canals C; Rosselet A; Conde E; Varela R; Cwynarski K; Gabriel I; Genet P; Guillerm G; Allione B; Ferrant A; Biron P; Espigado I; Serrano D; Sureda A
    J Clin Oncol; 2009 May; 27(13):2192-8. PubMed ID: 19332732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.